Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.

Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J.

Pain. 2003 Dec;106(3):337-45. Review.

PMID:
14659516
2.

Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations.

McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, Eccleston C, Finley GA, Goldschneider K, Haverkos L, Hertz SH, Ljungman G, Palermo T, Rappaport BA, Rhodes T, Schechter N, Scott J, Sethna N, Svensson OK, Stinson J, von Baeyer CL, Walker L, Weisman S, White RE, Zajicek A, Zeltzer L; PedIMMPACT.

J Pain. 2008 Sep;9(9):771-83. doi: 10.1016/j.jpain.2008.04.007. Epub 2008 Jun 17.

PMID:
18562251
3.

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.

Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT.

Pain. 2005 Jan;113(1-2):9-19. Review. No abstract available.

PMID:
15621359
4.

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S.

J Pain. 2008 Feb;9(2):105-21. Epub 2007 Dec 11.

PMID:
18055266
5.

Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain.

Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, Cleeland CS, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA.

Pain. 2008 Jul 15;137(2):276-85. Epub 2007 Oct 15.

PMID:
17937976
6.

What should be the core outcomes in chronic pain clinical trials?

Turk DC, Dworkin RH.

Arthritis Res Ther. 2004;6(4):151-4. Epub 2004 Jun 4. Review.

7.

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations.

Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, Chappell A, Chartier K, Cleeland CS, Costello A, Cowan P, Dimitrova R, Ellenberg S, Farrar JT, French JA, Gilron I, Hertz S, Jadad AR, Jay GW, Kalliomäki J, Katz NP, Kerns RD, Manning DC, McDermott MP, McGrath PJ, Narayana A, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Reeve BB, Rhodes T, Sampaio C, Simpson DM, Stauffer JW, Stucki G, Tobias J, White RE, Witter J.

Pain. 2010 May;149(2):177-93. doi: 10.1016/j.pain.2010.02.018. Epub 2010 Mar 6. Review.

PMID:
20207481
8.

IMMPACT recommendations for clinical trials: opportunities for the RDC/TMD.

Haythornthwaite JA.

J Oral Rehabil. 2010 Oct;37(10):799-806. doi: 10.1111/j.1365-2842.2010.02152.x.

PMID:
20887278
9.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
10.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
11.

New strategies in evaluation of therapeutic efficacy in fibromyalgia syndrome.

Ozgocmen S.

Curr Pharm Des. 2006;12(1):67-71. Review.

PMID:
16454726
12.

Comparing patients' and clinician-researchers' outcome choice for psychological treatment of chronic pain.

Beale M, Cella M, Williams AC.

Pain. 2011 Oct;152(10):2283-6. doi: 10.1016/j.pain.2011.06.007. Epub 2011 Jul 8. Review.

PMID:
21741768
13.

Reporting of IMMPACT-recommended core outcome domains among trials assessing opioids for chronic non-cancer pain.

Mulla SM, Maqbool A, Sivananthan L, Lopes LC, Schandelmaier S, Kamaleldin M, Hsu S, Riva JJ, Vandvik PO, Tsoi L, Lam T, Ebrahim S, Johnston BC, Olivieri L, Montoya L, Kunz R, Scheidecker A, Buckley DN, Sessler DI, Guyatt GH, Busse JW.

Pain. 2015 Sep;156(9):1615-9. doi: 10.1097/j.pain.0000000000000241.

PMID:
26020224
14.

Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials.

Turk DC, Dworkin RH, McDermott MP, Bellamy N, Burke LB, Chandler JM, Cleeland CS, Cowan P, Dimitrova R, Farrar JT, Hertz S, Heyse JF, Iyengar S, Jadad AR, Jay GW, Jermano JA, Katz NP, Manning DC, Martin S, Max MB, McGrath P, McQuay HJ, Quessy S, Rappaport BA, Revicki DA, Rothman M, Stauffer JW, Svensson O, White RE, Witter J.

Pain. 2008 Oct 31;139(3):485-93. doi: 10.1016/j.pain.2008.06.025. Epub 2008 Aug 15. Review.

PMID:
18706763
15.

Advice for the management of low back pain: a systematic review of randomised controlled trials.

Liddle SD, Gracey JH, Baxter GD.

Man Ther. 2007 Nov;12(4):310-27. Epub 2007 Mar 28. Review.

PMID:
17395522
16.
17.

Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations.

Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, Farrar JT, Hertz S, Raja SN, Rappaport BA, Rauschkolb C, Sampaio C.

Pain. 2009 Dec;146(3):238-44. doi: 10.1016/j.pain.2009.08.019. Review.

PMID:
19836888
18.

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D.

Ann Rheum Dis. 2008 Oct;67(10):1360-4. doi: 10.1136/ard.2008.091454.

PMID:
18791055
19.

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T.

Health Technol Assess. 2004 Jun;8(24):iii-x, 1-125. Review.

20.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

Supplemental Content

Support Center